Non Invasive Diabetes Therapy MarketSize and Trends

The role of non-invasive therapy for diabetes market has been on a positive growth path in healthcare industry since 2014. Though the non-invasive therapy concept was brought way back in 1980, the market has not gained much attention leading to development of fewer such devices. DexCom's seven system and Medtronic's Guardian real-time glucose monitoring system are two such products developed and marketed worldwide. The influx of non-invasive therapy has reinforced the diabetes market in various ways ranging from economical cost incurred to patient treatment outcomes.

Many leading players along with new entrants are venturing in the market to capitalize and generate high ROI. As a result, noninvasive therapy market is expected to witness double digit growth rate over the forecast period.

Market Dynamics:

The World Health Organization projects diabetic population to reach 336 Mn by 2030 from 270 Mn in 2015. Increase in incidence rate of diabetic population will demand for non-invasive medication is expected to create favorable market opportunities for the players globally. Moreover, improving healthcare access along with focus on R&D could spur the overall non-invasive market size. Some companies are engaged in development of non-invasive system on photonic technology and occlusion spectroscopy technology.

The market will be further driven by changing macroeconomics and consumer preference. Healthcare expenditure has increased in developing regions. Large consumer base along with changing lifestyle is expected to create substantially new market opportunities for early entrants.

Market Trends: